JP6211603B2 - クルクミンを含有する改善された複合体および組成物 - Google Patents

クルクミンを含有する改善された複合体および組成物 Download PDF

Info

Publication number
JP6211603B2
JP6211603B2 JP2015513962A JP2015513962A JP6211603B2 JP 6211603 B2 JP6211603 B2 JP 6211603B2 JP 2015513962 A JP2015513962 A JP 2015513962A JP 2015513962 A JP2015513962 A JP 2015513962A JP 6211603 B2 JP6211603 B2 JP 6211603B2
Authority
JP
Japan
Prior art keywords
curcumin
complex
phospholipid
oil
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015513962A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015518862A (ja
JP2015518862A5 (enExample
Inventor
ハロルド・ゴードン・ケイヴ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2015518862A publication Critical patent/JP2015518862A/ja
Publication of JP2015518862A5 publication Critical patent/JP2015518862A5/ja
Application granted granted Critical
Publication of JP6211603B2 publication Critical patent/JP6211603B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2015513962A 2012-05-22 2013-05-22 クルクミンを含有する改善された複合体および組成物 Expired - Fee Related JP6211603B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ600146 2012-05-22
NZ60014612 2012-05-22
PCT/NZ2013/000086 WO2013176555A1 (en) 2012-05-22 2013-05-22 Improved complexes and compositions containing curcumin

Publications (3)

Publication Number Publication Date
JP2015518862A JP2015518862A (ja) 2015-07-06
JP2015518862A5 JP2015518862A5 (enExample) 2016-01-14
JP6211603B2 true JP6211603B2 (ja) 2017-10-11

Family

ID=49624145

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015513962A Expired - Fee Related JP6211603B2 (ja) 2012-05-22 2013-05-22 クルクミンを含有する改善された複合体および組成物

Country Status (10)

Country Link
US (1) US20150104503A1 (enExample)
EP (2) EP3666265A1 (enExample)
JP (1) JP6211603B2 (enExample)
KR (2) KR20190090075A (enExample)
CN (3) CN110870857A (enExample)
AU (1) AU2013264466B2 (enExample)
CA (1) CA2910089A1 (enExample)
HK (1) HK1208375A1 (enExample)
IN (1) IN2014MN02552A (enExample)
WO (1) WO2013176555A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013220974A1 (de) * 2013-10-16 2015-04-16 Briu Gmbh Zusammensetzung zur oralen Administration von Curcumin
JP6987528B2 (ja) * 2017-05-12 2022-01-05 小林製薬株式会社 クルクミノイド含有錠剤
CN109846865B (zh) * 2018-12-26 2022-03-25 晨光生物科技集团股份有限公司 一种姜黄素制剂及其制备方法
CN109589410B (zh) * 2018-12-26 2022-02-01 晨光生物科技集团股份有限公司 一种姜黄素制剂及其制备方法
KR102169710B1 (ko) * 2020-01-08 2020-10-26 제주대학교 산학협력단 커큐민 나노스피어, 그 제조방법 및 이의 용도
WO2021203878A1 (zh) * 2020-04-10 2021-10-14 上海利统生化制品有限公司 一种缓解视疲劳的可食用组合物
US12357665B2 (en) * 2020-09-11 2025-07-15 Tzung-Yan Pharmaceutical compositions and uses thereof in treating muscle atrophy
EP4251136A1 (en) * 2020-11-24 2023-10-04 Specchiasol S.r.l. Formulation for oral administration of active compounds with low bioavailability and corresponding production method
WO2023055005A1 (ko) * 2021-09-28 2023-04-06 (주) 바이노텍 입자 표면이 개질된 커큐민 나노 입자 복합체 및 이의 제조 방법
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use
WO2023161955A1 (en) * 2022-02-28 2023-08-31 Gidaa Life Sciences Pvt. Ltd. A phytoactive encapsulated formulation for neurodegenerative diseases
CN115813780B (zh) * 2022-03-30 2024-08-13 广东格烯生物科技股份有限公司 一种含四氢姜黄素的纳米级祛黄组合物及其制备方法
IT202200025767A1 (it) 2022-12-15 2024-06-15 Prolabin & Tefarm S R L Formulazione comprendente polifenoli vanilloidi supportati su solidi lamellari per ridurre i livelli plasmatici di CGRP e sue applicazioni.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1201149B (it) * 1987-01-14 1989-01-27 Indena Spa Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche
CN1283237C (zh) * 2004-11-22 2006-11-08 山东大学 姜黄素磷脂复合物及其制备方法
US7759325B2 (en) 2005-04-18 2010-07-20 Sc Dicophar Use of lecithin as a medication for the treatment of psoriasis
WO2007098118A2 (en) * 2006-02-16 2007-08-30 Byron Robinson Pharmaceutical, Inc. Antineoplastic and curcumin derivatives and methods of preparation and use
PL1993365T3 (pl) * 2006-03-06 2013-10-31 Univ California Preparaty z biodostępnych kurkuminoidów do leczenia choroby alzheimera oraz innych zaburzeń powiązanych z wiekiem
EP1837030A1 (en) * 2006-03-09 2007-09-26 INDENA S.p.A. Phospholipid complexes of curcumin having improved bioavailability
AU2007275660B2 (en) * 2006-07-19 2012-08-02 The Board Of Regents Of The University Of Texas System Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease
IT1395086B1 (it) * 2009-03-11 2012-09-05 Velleja Res Srl Composizioni comprendenti curcumina in forma complessata con fosfolipidi e piperina ad azione chemio-sensibilizzante

Also Published As

Publication number Publication date
EP3666265A1 (en) 2020-06-17
CN110870857A (zh) 2020-03-10
KR20190090075A (ko) 2019-07-31
EP2852395A4 (en) 2015-12-16
WO2013176555A1 (en) 2013-11-28
AU2013264466A2 (en) 2016-01-21
HK1208375A1 (en) 2016-03-04
AU2013264466A1 (en) 2015-01-22
CA2910089A1 (en) 2013-11-28
JP2015518862A (ja) 2015-07-06
AU2013264466B2 (en) 2017-09-07
US20150104503A1 (en) 2015-04-16
IN2014MN02552A (enExample) 2015-07-24
CN104540515A (zh) 2015-04-22
CN111407752A (zh) 2020-07-14
KR20150035730A (ko) 2015-04-07
EP2852395A1 (en) 2015-04-01

Similar Documents

Publication Publication Date Title
JP6211603B2 (ja) クルクミンを含有する改善された複合体および組成物
JP2015518862A5 (enExample)
US20070122452A1 (en) Fat composition
Mangrulkar et al. A comprehensive review on pleiotropic effects and therapeutic potential of soy lecithin
JP2007504197A (ja) ホスファチジルセリン塩基の生理学的活性組成物
US20150110866A1 (en) Complexes and compositions containing curcumin
WO2015121378A1 (en) Liquid phospholipid-containing compositions for the preparation of pharmaceuticals
JP4913340B2 (ja) カプセル剤
US10960016B2 (en) Capsules containing high doses of krill phospholipids
JP6949670B2 (ja) 難溶性物質を含有する経口摂取用組成物、難溶性物質の消化管吸収性の向上方法及び難溶性物質を含有する水中油型乳化物の胃内での乳化安定化方法
NZ610906A (en) Improved complexes and compositions containing curcumin
EP3206677A1 (en) Monounsaturated fatty acid compositions and use for treating atherosclerosis
CN103859395A (zh) 一种高吸收率的辅酶q10的自乳化释药体系及其制备方法及应用
NZ610906B (en) Improved complexes and compositions containing curcumin
JP5221114B2 (ja) ソフトカプセル剤
JP4969989B2 (ja) リン脂質組成物およびこれを含有する食品組成物、医薬品組成物、並びにその製造方法
TW200904456A (en) Organic compounds
WO2015185238A1 (en) Homogeneous formulation comprising omega-3 polyunsatured fatty acid and resveratrol for oral administration
WO2023275190A1 (en) Soft gel capsule
KR20250089549A (ko) 치료 화합물의 전달을 위한 인지질 조성물
CN110139645A (zh) 用于预防和/或治疗恶病质的ω-3脂肪酸组合物
WO2011124895A2 (en) Phospholipid-containing pharmaceutical and nutraceutical compositions
WO2018146060A1 (en) Long-term efficacy of liver disease treatment with epa and dha

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170727

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170814

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170913

R150 Certificate of patent or registration of utility model

Ref document number: 6211603

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees